Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07638878
NCT07638878Active, not recruitingNot Applicable

Exploring the Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer Who Are Ineligible for Curative Surgery

Guangzhou Medical University1 site in 1 country30 target enrollmentStarted: November 6, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
30
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Ages 18-75 years (inclusive), regardless of gender;
  • •Locally advanced (Stage IIIB, IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) confirmed by histology as inoperable for curative intent (according to the 8th edition of the IASLC TNM staging system);
  • •Or histologically confirmed inoperable mixed small cell lung cancer containing non-small cell lung cancer components;
  • •KRAS gene mutation-positive;
  • •KRAS mutation-positive lung cancer not amenable to radical surgery, treated with tislelizumab in combination with nab-paclitaxel and platinum chemotherapy.

Exclusion Criteria

  • •Patients with incomplete key baseline information and treatment data.
  • •Patients who refuse to provide written informed consent (ICF).

Investigators

Sponsor
Guangzhou Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Haihong Yang, MD, Pricipal investigator

Chief Physician

Guangzhou Medical University

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 2
Phase II study: efficacy and safety of tislelizumab in patients with de novo Hodgkin lymphoma unsuitable for standard chemotherapyHodgkin lymphoma
2022-503090-11-00Fondazione Italiana Linfomi Onlus25
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesAdvanced Unresectable Gastric AdenocarcinomaEsophageal Squamous Cell CarcinomaAdvanced Gastroesophageal Adenocarcinoma
NCT07554521BeOne Medicines30
Recruiting
Phase 2
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ AdenocarcinomaGastric or Esophagogastric Junction Adenocarcinoma
NCT07569068Ruijin Hospital88
Recruiting
Phase 3
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.752
Not yet recruiting
Phase 2
Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07388758Sun Yat-sen University37